Calcitonin gene-related peptide gene therapy
Latest Information Update: 01 May 2002
At a glance
- Originator Nonindustrial source
- Class Gene therapies; Neuropeptides
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cerebrovascular disorders
Most Recent Events
- 31 Oct 2000 New profile
- 31 Oct 2000 Preclinical development for Cerebrovascular disorders in USA (Unknown route)